S14 Ep52: FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

OncLive® On Air - Un podcast de OncLive® On Air

Podcast artwork

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Visit the podcast's native language site